Keigo Higashino: A Literary Farewell and the Facts About Colorectal Screening
NHK confirmed the novelist's death from colorectal cancer at 68. His work is remembered separately from evidence-based guidance on screening, symptoms and treatment.
The 60-second version
NHK confirmed that Keigo Higashino died from colorectal cancer at 68; his literary record can be remembered while keeping general health guidance separate from his private medical history.
Key points
- The Devotion of Suspect X received the 134th Naoki Prize, according to the official award list.
- USPSTF recommends screening average-risk, asymptomatic U.S. adults from 45 through 75; colonoscopy every 10 years is one option after a normal high-quality examination.
- Symptoms such as blood in stool or persistent bowel-habit changes require medical evaluation, not a wait for routine screening.
- Higher-risk people need individualized timing, and treatment depends on stage, location, molecular features and overall health.
- SEER survival figures are population statistics and cannot predict one person's outcome.
Verdict. Keep the obituary, literary assessment and medical guidance distinct: verify the first, label the second as interpretation, and make the third precise enough to support informed medical discussion.
ObituaryWhat has been confirmed
NHK reported on July 27 that Japanese novelist Keigo Higashino had died four days earlier from colorectal cancer, aged 68. He was born in Osaka and was a recipient of the Naoki Prize.
LiteratureThe moral pressure beneath the mystery
For many readers, Higashino's novels made mystery fiction feel both rigorous and humane. Works including The Devotion of Suspect X, Malice and Journey Under the Midnight Sun place puzzles beside loyalty, responsibility and the consequences of human choices. That is literary assessment, separate from the confirmed facts of his death.
The official Naoki Prize list records The Devotion of Suspect X as the winner of the 134th Naoki Prize. It is a documented landmark in a career that reached readers far beyond Japan.
ScreeningScreening is for people without symptoms
Colorectal screening looks for cancer or precancerous changes before symptoms appear. Under U.S. Preventive Services Task Force guidance, average-risk, asymptomatic adults should begin screening at 45 and continue routinely through 75. This is U.S. guidance, and local recommendations may differ.
| Who the guidance covers | Average-risk adults without symptoms, ages 45–75 |
|---|---|
| One accepted option | A normal, high-quality colonoscopy every 10 years |
| Other options | Stool-based tests, CT colonography and sigmoidoscopy at their recommended intervals |
| Ages 76–85 | Decision individualized according to health, prior screening and preferences |
SymptomsSymptoms require evaluation, not routine screening
Blood in the stool or a persistent change in bowel habits can be signs of colorectal cancer, but they can also have other causes. Unexplained anemia, abdominal discomfort, fatigue or unintended weight loss also warrant medical attention. A symptomatic person needs clinical evaluation rather than waiting for a routine screening date.
RiskFamily and personal history change the plan
The age-45 recommendation is mainly for average-risk adults. A personal history of colorectal cancer or adenomatous polyps, inflammatory bowel disease, a significant family history, or a hereditary syndrome such as Lynch syndrome can require earlier or more frequent testing. The correct starting age and interval depend on the details and the local guideline.
TreatmentThere is no single colorectal cancer pathway
Treatment depends on the tumor's location, extent, molecular features, the person's overall health and preferences. NCI materials describe combinations of surgery, chemotherapy, radiation, targeted therapy and immunotherapy. Biomarkers can affect treatment choices, but no one therapy or prognosis applies to every patient.
OutcomesPopulation statistics are not individual forecasts
SEER reports five-year relative survival of about 91.3% for localized, 75.2% for regional and 16.2% for distant colorectal cancer in its current Stat Facts summary. These categories are not identical to numbered AJCC stages, and the figures describe groups treated in particular years—not the future of any individual patient.
ActionWhat can be done now
- Without symptoms: discuss an appropriate screening method from age 45 if you are at average risk, following the guideline used where you live.
- With symptoms: seek medical assessment rather than waiting for routine screening.
- With higher risk: ask for an individualized starting age, test and interval based on personal and family history.
Remembering a writer does not require turning his illness into a lesson about his private care. The responsible public-health conclusion is narrower: screening can reduce colorectal cancer incidence and mortality, warning signs deserve evaluation, and treatment decisions must be individualized.